Latest News
Sensorion secures French approval for Phase I/II SENS-601 hearing-loss trial
3 September 2026 - Sensorion (Euronext Growth Paris:ALSEN), a clinical-stage biotechnology company that specialises in hearing loss therapies, said on Thursday that it has received authorisation from France's National Agency for Medicines and He...
EpiVax introduces AI-enhanced models for immunogenicity prediction
3 September 2026 - EpiVax Inc, a provider of immunogenicity assessment and sequence optimisation for biologic therapeutics and vaccines, announced on Wednesday the release of AI-enabled enhancements to ISPRI, its proprietary in silico platform for as...
Foventa makes key CMO and CFO appointments
3 September 2026 - Foventa Therapeutics, a biotechnology company focused on novel therapies for retinal vascular diseases, announced on Wednesday that it has further strengthened its management team with the appointments of Dr Zaiba Malik as chief me...
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
3 September 2026 - Biopharmaceutical company Akeso Inc (HKEX:9926) announced on Wednesday that a pre-specified interim analysis in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee, met the key secondary endpoi...
Teva reports positive Phase 2a data for TEV '408 in celiac disease
2 September 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on Wednesday reported positive top-line results from an ongoing Phase 2a study of TEV '408, an investigational anti-interleukin-15 m...